Vaxart, Inc. (VXRT)
Vaxart, Inc. operates as a biotechnology firm currently in the clinical development phase, concentrating its efforts on identifying and advancing novel oral recombinant protein vaccines. The company leverages its unique proprietary platform for delivering these oral vaccine solutions. Its diverse pipeline showcases several promising candidates: An oral tablet vaccine targeting norovirus, which is presently undergoing Phase Ib clinical assessment for both GI.1 and GII.4 strains. A seasonal influenza vaccine, now in Phase II clinical studies, designed to address H1 influenza infections. A vaccine candidate against respiratory syncytial virus (RSV). A coronavirus vaccine, also advancing through Phase II clinical trials for SARS-CoV-2. Beyond infectious diseases, Vaxart is also engaged in formulating therapeutic vaccines aimed at treating cervical cancer and dysplasia associated with human papillomavirus. The company's main operations are situated in South San Francisco, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Vaxart, Inc.
- 1.0%
- 2.4M
- 3.95
Float 240.64M · Signal8 dilution snapshot · Nov 5, 2026
The cost to borrow VXRT shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 11.5%
- 436
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 2.4M sh |
| Oct 15, 2026 | 2.4M sh |
| Sep 30, 2026 | 2.3M sh |
| Sep 15, 2026 | 2.3M sh |
| Aug 31, 2026 | 2.3M sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 22, 2026 | 436 sh |
| Oct 14, 2026 | 2.9K sh |
| Oct 13, 2026 | 1.6K sh |
| Sep 28, 2026 | 625 sh |
| Sep 21, 2026 | 400 sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 11.5% |
| Nov 16, 2026 | 39.1% |
| Nov 13, 2026 | 6.5% |
| Nov 12, 2026 | 29.7% |
| Nov 11, 2026 | 28.6% |
130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for VXRT: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 2,417,496 VXRT shares were sold short (1.00% of a 240.64M-share float, 3.95 days to cover).